Actis Oncology represents a promising, de-risked investment opportunity in the radio-pharmaceutical sector due to its platform-based approach and specific target validation.

“The company has designed a platform that can carry any radioactive payload, is complex enough to go after a variety of targets, and small enough to clear your body with minimal side effects. The beautiful thing about this approach is that physicians can verify target engagement in early clinical tri”